Cosmo NVSTU:C43 +1.10%81 9-Day RSI is 48.70 as of Jul. 08, 2026. GuruFocus rates STU:C43 with a GF Score™ of 81/100 and a GF Value™ of €46.62 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,047 Drug Manufacturers companies, Cosmo NV ranks better than 63.13% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-08), Cosmo NV's 9-Day RSI is 48.70.
The industry rank for Cosmo NV's 9-Day RSI or its related term are showing as below:
STU:C43's 9-Day RSI is ranked better than 63.13% of 1047
companies
in the Drug Manufacturers industry
Industry Median: 50.3
vs STU:C43: 48.70
Cosmo NV (STU:C43) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Cosmo NV 9-Day RSI Related Terms
STU:C43 vs LLY, JNJ, ABBV: 9-Day RSI Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Cosmo NV's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo NV (STU:C43) has a 9-Day RSI of 48.70 as of Jul. 08, 2026. According to the industry distribution chart, Cosmo NV ranks #386 out of 1047 companies in the Drug Manufacturers industry, placing it in the top 36.9%.
Is Cosmo NV's 9-Day RSI too high?
Cosmo NV's current 9-Day RSI is 48.70. The Drug Manufacturers industry median 9-Day RSI is 50.30. Cosmo NV's value of 48.70 is 3.2% below this industry median. Based on the distribution chart, Cosmo NV ranks #386 out of 1047 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cosmo NV has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's 9-Day RSI compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #386 out of 1047 companies for 9-Day RSI. This puts Cosmo NV in the upper half of its industry. The industry median 9-Day RSI is 50.30. Cosmo NV's value of 48.70 is 3.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 50.30, based on 1,047 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current 9-Day RSI of 48.70 is 3.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 50.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current 9-Day RSI is 48.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (STU:C43) is currently considered Significantly Overvalued. The stock's GF Value™ is €46.62, compared to a current price of €73.60 — trading 57.9% above its estimated fair value. The current 9-Day RSI is 48.70 and 3.2% below the Drug Manufacturers industry median of 50.30. Cosmo NV's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Cosmo NV (STU:C43), the current 9-Day RSI is 48.70 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (STU:C43) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of €73.60 is trading 57.9% above its estimated GF Value™ of €46.62.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for STU:C43:
9-Day RSI: 48.70
GF Value™: €46.62 vs. price of €73.60 (57.9% above fair value)
Industry Position: 3.2% below the Drug Manufacturers median (#386 of 1047)
No single metric tells the full story. See the STU:C43 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
81GF Score
Get the complete analysis for STU:C43
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:C43 has been successfully added to your 